Qianjin Pharmaceutical announced that the company's subsidiaries, Qianjin Xiangjiang Pharmaceutical and Qianjin Xieli Pharmaceutical, have received “Drug Registration Certificates” for minoxidil linimide tablets, amlodipine benazepril capsules, and ursodeoxycholic acid capsules approved and issued by the State Drug Administration. Among them, Qianjin Xiangjiang Pharmaceutical is the marketing license holder for minoxidil liniment and ezhemab tablets, with a corresponding cumulative R&D investment of 5,6273 million yuan and 5,54331 million yuan respectively; Qianjin Xieli Pharmaceutical is the marketing license holder for ursodeoxycholic acid capsules and amlodipine benazepril capsules, with corresponding cumulative R&D investments of 9.797 million yuan and 1,728,600 yuan respectively.

Qianjin Pharmaceutical announced that the company's subsidiaries, Qianjin Xiangjiang Pharmaceutical and Qianjin Xieli Pharmaceutical, have received “Drug Registration Certificates” for minoxidil linimide tablets, amlodipine benazepril capsules, and ursodeoxycholic acid capsules approved and issued by the State Drug Administration. Among them, Qianjin Xiangjiang Pharmaceutical is the marketing license holder for minoxidil liniment and ezhemab tablets, with a corresponding cumulative R&D investment of 5,6273 million yuan and 5,54331 million yuan respectively; Qianjin Xieli Pharmaceutical is the marketing license holder for ursodeoxycholic acid capsules and amlodipine benazepril capsules, with corresponding cumulative R&D investments of 9.797 million yuan and 1,728,600 yuan respectively.